Robin Jones to Neoadjuvant Therapy
This is a "connection" page, showing publications Robin Jones has written about Neoadjuvant Therapy.
Connection Strength
2.283
-
Sarcoma: Does histotype-tailored neoadjuvant therapy improve outcomes? Nat Rev Clin Oncol. 2017 10; 14(10):589-590.
Score: 0.568
-
Neoadjuvant chemotherapy in localised soft-tissue sarcomas: where do we go from here? Lancet Oncol. 2017 06; 18(6):706-707.
Score: 0.561
-
The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat. 2009 Jul; 116(1):53-68.
Score: 0.302
-
Neoadjuvant treatment for early-stage breast cancer: opportunities to assess tumour response. Lancet Oncol. 2006 Oct; 7(10):869-74.
Score: 0.268
-
Future Directions in the Treatment of Osteosarcoma. Cells. 2021 01 15; 10(1).
Score: 0.180
-
Treatment of retroperitoneal sarcoma: current standards and new developments. Curr Opin Oncol. 2017 07; 29(4):260-267.
Score: 0.141
-
Current and advancing systemic treatment options for soft tissue sarcomas. Expert Opin Pharmacother. 2015; 16(13):2023-37.
Score: 0.119
-
Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer. Breast Cancer Res Treat. 2010 Jan; 119(2):315-23.
Score: 0.079
-
Clinicopathological features and treatment outcome of oesophageal gastrointestinal stromal tumour (GIST): A large, retrospective multicenter European study. Eur J Surg Oncol. 2021 08; 47(8):2173-2181.
Score: 0.046
-
Methylated NEUROD1 promoter is a marker for chemosensitivity in breast cancer. Clin Cancer Res. 2008 Jun 01; 14(11):3494-502.
Score: 0.019